Niraula S,Ocana A,Ennis M,et al.Body size and breast cancer prognosis in relation to hormone receptor and menopausal status:a meta-analysis[J].Breast Cancer Res Treat,2012,134(2):769-781.
[2]
Folkerd EJ,Dixon JM,Renshaw L,et al.Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer[J].J Clin Oncol,2012,30(24):2 977-2 980.
[3]
Pfeiler G,Konigsberg R,Fesl C,et al.Impact of body mass indexon the efficacy of endocrine therapy in premenopausal patients with breast cancer:an analysis of the prospective ABCSG-12trial[J].J Clin Oncol,2011,29(19):2 653-2 659.
[4]
Ioannides SJ,Barlow PL,Elwood JM,et al.Effect of obesity on aromatase inhibitor efficacy in postmenopausal,hormone receptor-positive breast cancer:a systematic review[J].Breast Cancer Res Treat,2014,147(2):237-248.
[5]
Sestak I,Distler W,Forbes JF,et al.Effect of body mass index on recurrences in tamoxifen and anastrozole treated women:anexploratory analysis from the ATAC trial[J].J Clin Oncol,2010,28(21):3 411-3 415.
[6]
Morris PG,Hudis CA,Giri D,et al.Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer[J].Cancer Prev Res(Phila),2011,4(7):1 021-1 029.
[7]
Parr CL,Batty GD,Lam TH,et al.Body-mass index and cancerr mortality in the Asia-Pacific Cohort Studies Collaboration:pooled analyses of 424,519participants[J].Lancet Oncol,2010,11(8):741-752.
[8]
Protani M,Coory M,Martin JH.Effect of obesity on survival of women with breast cancer:systematic review and meta-analysis[J].Breast Cancer Res Treat,2010,123(3):627-635.
[9]
de Azambuja E,McCaskill-Stevens W,Francis P,et al.The effect of body mass index on overall and diseasefree survivalin node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy:the experience of the BIG 02-98trial[J].Breast Cancer Res Treat,2010,119(1):145-153.
[10]
Lonning PE,Haynes BP,Dowsett M.Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors[J].Eur J Cancer,2014,50(6):1 055-1 064.
[11]
Osborne CK,Schiff R.Mechanisms of endocrine resistance in breast cancer[J].Annu Rev Med,2011,62:233-247.
[12]
De Luca A,Lamura L,Gallo M,et al.Mesenchymal stem cell-derived interleukin-6and vascular endothelial growth factor promote breast cancer cell migration[J].J Cell Biochem,2012,113(11):3 363-3 370.
[13]
Amadou A,Hainaut P,Romieu I.Role of obesity in the risk of breast cancer:lessons from anthropometry[J].J Oncol,2013,2013:906495.
[14]
Goldberg JE,Schwertfeger KL.Proinflammatory cytokines in breast cancer:mechanisms of action and potential targets for therapeutics[J].Curr Drug Targets,2010,11(9):1 133-1 146.
[15]
National Health Institute.Obesity and cancer risk.Secondary obesity and cancer risk[EB/OL].[2005-11-17].http://www.cancer.gov/cancertopics/factsheet/risk/obesity.
[16]
Jemal A,Center MM,DeSantis C,et al.Global patterns of cancer incidence and mortality rates and trends[J].Cancer Epidemiol Biomarkers Prev,2010,19(8):1 893-1 907.
[17]
Sabnis GJ,Goloubeva O,Chumsri S,et al.Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole[J].Cancer Res,2011,71(5):1 893-1 903.
[18]
Wolters R,Schwentner L,Regierer A,et al.Endocrine therapy in obese patients with primary breast cancer:another piece of evidence in an unfinished puzzle[J].Breast Cancer Res Treat,2012,131(3):925-931.
[19]
Cavazzoni A,Bonelli MA,Fumarola C,et al.overcoming acquired resistance to letrozole by targeting the PI3K/Akt/Mtor pathway in breast cancer cell clones[J].Cancer Lett,2012,323(1):77-87.
[20]
Suzuki R,Saji S,Toi M.Impact of body mass index on breast cancer in accordance with the life-stage of women[J].Front Oncol,2012,2:123.
Subbaramaiah K,Howe LR,Bhardwaj P,et al.Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland[J].Cancer Prev Res(Phila),2011,4(3):329-346.
[23]
Bowers LW,Cavazos DA,Maximo IX,et al.Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression[J].Breast Cancer Res,2013,15(4):R59.
[24]
Goodwin PJ,Ennis M,Pritchard KI,et al.Insulin-and obesity-related variables in early-stage breast cancer:correlations and time course of prognostic associations[J].J Clin Oncol,2012,30(2):164-171.
Dubois V,Delort L,Billard H,et al.Breast cancer and obesity:in vitro interferences between adipokines and proangiogenic features and/or antitumor therapies[J].PLoS One,2013,8(3):e58541.
[27]
Gnant M,Pfeiler G,Stoger H,et al.The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer:an analysis of the randomised ABCSG-6atrial[J].Br J Cancer,2013,109(3):589-596.
